PHP
IMUX icon

Parkman Healthcare Partners’s Immunic IMUX Stock Holding History

Parkman Healthcare Partners’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,226
Closed -$153K – 108
2023
Q4 		$153K Sell
10,226
-46,025
-82% -$564K 0.02% 88
2023
Q3 		$827K Buy
56,251
+2,276
+4% +$43.8K 0.15% 93
2023
Q2 		$1.35M Buy
53,975
+7,998
+17% +$134K 0.23% 84
2023
Q1 		$685K Hold
45,977
– – 0.15% 76
2022
Q4 		$644K Sell
45,977
-19,787
-30% -$540K 0.17% 76
2022
Q3 		$2.08M Buy
65,764
+761
+1% +$31.9K 0.59% 54
2022
Q2 		$2.26M Sell
65,003
-43,922
-40% -$2.81M 0.83% 41
2022
Q1 		$12.3M Buy
108,925
+11,507
+12% +$1.33M 3.6% 5
2021
Q4 		$9.32M Buy
97,418
+5,009
+5% +$451K 2.06% 19
2021
Q3 		$8.18M Buy
92,409
+51,000
+123% +$5.02M 2.07% 18
2021
Q2 		$5.08M Buy
41,409
+1,287
+3% +$178K 1.11% 35
2021
Q1 		$6.39M Buy
40,122
+3,453
+9% +$586K 1.48% 23
2020
Q4 		$5.61M Sell
36,669
-3,333
-8% -$599K 1.44% 27
2020
Q3 		$7.43M Buy
40,002
+26,002
+186% +$4.26M 1.97% 18
2020
Q2 		$1.7M Buy
+14,000
New +$1.42M 0.48% 60

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Parkman Healthcare Partners's IMUX Position: Q1 2024 in Review

Parkman Healthcare Partners sold out of Immunic (IMUX) in Q1 2024, closing a stake of 10,226 shares — an estimated $153K sold.

Parkman Healthcare Partners first reported a position in IMUX in Q2 2020 and held it in 15 quarters. The position peaked at $12.3M in Q1 2022. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2024.

  • Parkman Healthcare Partners reported no remaining Immunic position as of Q1 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 10,226 Immunic shares in Q1 2024, an estimated $153K.
  • Parkman Healthcare Partners first reported a position in Immunic in Q2 2020 and held it in 15 quarters.
  • Parkman Healthcare Partners's Immunic position peaked at $12.3M in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Immunic as of Q1 2024.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.